StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.67+0.15 (+0.49%)

Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%

Pfizer Tukysa (tucatinib by Year

Tukysa (tucatinib — HER2+ breast/colorectal cancer, via Seagen) — Worldwide revenues ($M) ($M)

QuarterlyAnnual

Pfizer Tukysa (tucatinib: $463M in FY2025, down 3.5% from a year earlier.

Latest, FY2025
463
Period ended Dec 31, 2025
Change on a year earlier
-3.5%
480 in FY2024
History
5 years
Since FY2021
Sources
4
Documents cited below

Where the FY2025 figure comes from

“|| Tukysa | 463 | 480 | (4%) | (4%) | 352 | 389 | (10%) | 111 | 91 | 22% | 18%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTukysa (tucatinib — HER2+ breast/colorectal cancer, via Seagen) — Worldwide revenues ($M) ($M)Year on yearSource
FY2025Dec 31, 2025463-3.5%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
FY2024Dec 31, 2024480+2,566.7%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
FY2023Dec 31, 202318–Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
FY2022Dec 31, 20220–Form 10-K (filed 2025-02-27) ↗
FY2021Dec 31, 20210–Form 10-K (filed 2024-02-22) ↗

Breakdown

What makes up tukysa (tucatinib

Cite this data

StockData. (2026). Pfizer Tukysa (tucatinib ($M), annual FY2021–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/tukysa-ww

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.